What is C/T Blend?
The C/T blend combines two structurally optimized peptide analogues—Cagrilintide, a long acting amylin receptor agonist, and Tirzepatide, a dual GIP/GLP-1 receptor agonist— engineered to enhance pharmacological stability and extend half-lives suitable for once-weekly administration. Cagrilintide achieves its extended pharmacokinetic profile through multiple stabilizing mutations, such as 14E/17R for α-helix integrity and proline substitutions that inhibit β-sheet formation, alongside N-terminal lipidation (Kruse et al. 2021; D’Ascanio et al. 2024). It binds amylin receptor subtypes (AMY1R–3R) and the calcitonin receptor (CTR) via a conserved mid-segment motif and shows structural enhancements at residues like Pro37, which modulate receptor engagement and dynamics (Cao et al. 2025).
Tirzepatide, a 39-amino acid synthetic peptide, similarly features C20 fatty diacid modification for albumin binding, yielding a half-life of approximately five days (Chavda et al. 2022). Its dual receptor affinity preferentially targets GIP receptors while maintaining GLP-1 activity, resulting in robust metabolic effects in experimental models (Min & Bain 2020). In preclinical contexts, the combination of Cagrilintide and GLP-1 analogues has demonstrated additive effects, indicating potential mechanistic synergy when co-administered with dual incretin receptor agonists (D’Ascanio et al. 2024). The pairing of Cagrilintide’s amylinergic modulation with Tirzepatide’s incretin-based pathways presents a complementary approach to the investigation of integrated energy balance and metabolic regulation.
References
Cao, J., Belousoff, M. J., Johnson, R. M., Keov, P., Mariam, Z., Deganutti, G., Christopoulos, G., Hick, C. A., Reedtz-Runge, S., Glendorf, T., Ballarín-González, B., Raun, K., Bayly-Jones, C., Wootten, D., & Sexton, P. M. (2025). Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications, 16, Article 3389. https://doi.org/10.1038/s41467-025-58680-y
Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022). Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini review. Molecules, 27(13), 4315. https://doi.org/10.3390/molecules27134315
D’Ascanio, A. M., Mullally, J. A., & Frishman, W. H. (2024). Cagrilintide: A long-acting amylin analog for the treatment of obesity. Cardiology in Review, 32(1), 83–90. https://doi.org/10.1097/CRD.0000000000000513
Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., de la Cour, C. D., Clausen, T. R., Johansson, E., Fulle, S., Skyggebjerg, R. B., & Raun, K. (2021). Development of cagrilintide, a long-acting amylin analogue. Journal of Medicinal Chemistry, 64(17), 11183–11194. https://doi.org/10.1021/acs.jmedchem.1c00565
Min, T., & Bain, S. C. (2020). The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. Diabetes Therapy, 11(9), 1941–1957. https://doi.org/10.1007/s13300-020-00981-0
More Information
Product Usage
